Abstract
Auteur(s) : Tomoe Kuhara1, Daisuke Watanabe1, Yusuke Iwahori2, Yasuhiko Tamada1, Masahiro Yamamura2, Yoshinari Matsumoto1 1Department of Dermatology, Aichi medical University, Nagakute, Aichi, 480-1195 Japan 2Department of Rheumatology, Aichi medical University, Nagakute, Aichi, Japan Tumor necrosis factor (TNF) antagonists, including monoclonal antibodies (infliximab and adalimumab) and soluble TNF-α receptor antagonists (etanercept), are successfully utilized in the treatment of a [...]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
